Synucleinopathies from bench to bedside

Parkinsonism and Related Disorders

Volumn 18, Issue SUPPL. 1, 2012, Pages

  Puschmann, Andreas ^a,b   Bhidayasiri, Roongroj ^c   Weiner, William J ^d  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c KING CHULALONGKORN MEMORIAL HOSPITAL   (Thailand)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Attention deficit hyperactivity disorder; Dementia with Lewy bodies; Multiple system atrophy; Parkinson's disease; Synucleinopathies

Indexed keywords

ALPHA SYNUCLEIN;

ARTICLE; ATTENTION DEFICIT DISORDER; DEMENTIA; DIFFUSE LEWY BODY DISEASE; DOPPLER ECHOGRAPHY; GENE; GENE MUTATION; HEREDITY; HUMAN; LRRK2 GENE; MYOCLONUS; NEUROLOGIC DISEASE; NEUROPATHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; ONSET AGE; PARASOMNIA; PARKIN GENE; PARKINSON DISEASE; PARKINSONISM; PATIENT IDENTIFICATION; PINK1 GENE; POINT OF CARE TESTING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; RESTLESS LEGS SYNDROME; SCNA GENE; SHY DRAGER SYNDROME; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SMELLING DISORDER; SYNUCLEINOPATHY; BRAIN ATROPHY; CEREBROSPINAL FLUID ANALYSIS; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; GAUCHER DISEASE; GLIA; LYSOSOME STORAGE DISEASE; NEUROIMAGING; OLIGOMERIZATION; PERSONALITY DISORDER; PROTEIN AGGREGATION; SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY; SNCA GENE; TRANSCRANIAL DOPPLER ULTRASONOGRAPHY;

EID: 84858662511     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/s1353-8020(11)70010-4     Document Type: Article

References (20)

1. Halliday GM, Holton JL, Revesz T, Dickson DW. Neuropathology underlying clinical variability in patients with synucleinopathies. Acta Neuropathol 2011 Aug;122(2):187-204.
2. Danzer KM, McLean PJ. Drug targets from genetics: alpha-synuclein. CNS Neurol Disord Drug Targets 2011 Aug 15 [Epub ahead of print].
3. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003 Mar-Apr;24(2):197-211.
4. Angot E, Brundin P. Dissecting the potential molecular mechanisms underlying alpha-synuclein cell-to-cell transfer in Parkinson's disease. Parkinsonism Relat Disord 2009 Dec;15(Suppl 3):S143-7.
5. Weiner WJ. There is no Parkinson disease. Arch Neurol 2008 Jun;65(6):705-8.
6. Hamilton RL. Lewy bodies in Alzheimer's disease: a neuropathological review of 145 cases using alpha-synuclein immunohistochemistry. Brain Pathol 2000 Jul;10(3):378-84.
7. Ahlskog JE. Parkin and PINK1 parkinsonism may represent nigral mitochondrial cytopathies distinct from Lewy body Parkinson's disease. Parkinsonism Relat Disord 2009 Dec;15(10):721-7.
8. Puschmann A, Pfeiffer RF, Stoessl AJ, Kuriakose R, Lash JL, Searcy JA, et al. A family with Parkinsonism, essential tremor, restless legs syndrome, and depression. Neurology 2011 May 10;76(19):1623-30.
9. Puschmann A, Wszolek ZK, Farrer M, Gustafson L, Widner H, Nilsson C. Alpha-synuclein multiplications with parkinsonism, dementia or progressive myoclonus? Parkinsonism Relat Disord 2009 Jun;15(5):390-2.
10. Puschmann A, Ross OA, Vilarino-Guell C, Lincoln SJ, Kachergus JM, Cobb SA, et al. A Swedish family with de novo alpha-synuclein A53T mutation: evidence for early cortical dysfunction. Parkinsonism Relat Disord 2009 Nov;15(9):627-32.
11. Brown RG, Lacomblez L, Landwehrmeyer BG, Bak T, Uttner I, Dubois B, et al. Cognitive impairment in patients with multiple system atrophy and progressive supranuclear palsy. Brain 2010 Aug;133(Pt 8):2382-93.
12. Uversky VN. Neuropathology, biochemistry, and biophysics of alpha-synuclein aggregation. J Neurochem 2007 Oct;103(1):17-37.
13. Nemani VM, Lu W, Berge V, Nakamura K, Onoa B, Lee MK, et al. Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis. Neuron 2010 Jan 14;65(1):66-79.
14. Goldstein DS, Sewell L, Holmes C. Association of anosmia with autonomic failure in Parkinson disease. Neurology 2010 Jan 19;74(3):245-51.
15. Boeve BF, Silber MH, Saper CB, Ferman TJ, Dickson DW, Parisi JE, et al. Pathophysiology of REM sleep behaviour disorder and relevance to neurodegenerative disease. Brain 2007 Nov;130(Pt 11):2770-88.
16. Golimstok A, Rojas JI, Romano M, Zurru MC, Doctorovich D, Cristiano E. Previous adult attention-deficit and hyperactivity disorder symptoms and risk of dementia with Lewy bodies: a case-control study. Eur J Neurol 2011 Jan;18(1):78-84.
17. Vernon AC, Ballard C, Modo M. Neuroimaging for Lewy body disease: is the in vivo molecular imaging of alpha-synuclein neuropathology required and feasible? Brain Res Rev 2010 Oct 5;65(1):28-55.
18. Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, Sixel-Doring F, Trenkwalder C, Schlossmacher MG. alpha-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol 2011 Mar;10(3):230-40.
19. Caviness JN, Lue LF, Beach TG, Hentz JG, Adler CH, Sue L, et al. Parkinson's disease, cortical dysfunction, and alpha-synuclein. Mov Disord 2011 Jul;26(8):1436-42.
20. Shachar T, Bianco CL, Recchia A, Wiessner C, Raas-Rothschild A, Futerman AH. Lysosomal storage disorders and Parkinson's disease: Gaucher disease and beyond. Mov Disord 2011 Aug 1;26(9):1593-604.